Home

/

News

/

Research

Seven Rinn Pharma & Biopharma Researchers Rank Among World’s Top 2% Scientists in 2026

November 18, 2026

Rinn Pharma & Biopharma has a strengthened position on the international research scene, with seven of its researchers named among the world’s top 2% of scientists in the 2026 Stanford-Elsevier ranking.

The prestigious list recognises the world’s most influential researchers based on standardised citation indicators derived from Scopus data. It includes researchers whose scientific contributions rank among the top 2% within their respective fields, reflecting the global impact and influence of their published research.

The ranking is based on data from the global Scopus database, and it assesses researchers according to several indicators of scientific impact, including citations, the h-index, and the quality of scientific publications based on the impact factors of the journals in which they are published.

The seven researchers recognised in the 2026 edition are:

  1. Professor Damien Thompson, UL
  2. Professor James Gleeson, UL
  3. Professor David Brayden, UCD
  4. Professor Marcus Baumann, UCD
  5. Professor Jonathan Bones, NIBRT
  6. Professor Kevin Kavanagh, MU
  7. Associate Professor Rob Elmes, MU

This recognition is a powerful testament to the strength, depth and international impact of research within Rinn Pharma & Biopharma. The inclusion of seven researchers from across its university and industry partner network highlights the centre’s sustained commitment to excellence in pharmaceutical and biopharmaceutical research, innovation and talent development.

Spanning areas including drug delivery, advanced therapeutics, continuous manufacturing, biopharmaceutical analysis, biomaterials and translational healthcare solutions, the work of these researchers is helping to address some of the most significant challenges facing the global life sciences sector. Their achievements reinforce Rinn Pharma & Biopharma’s position as a leading research centre, driving scientific discovery, fostering collaboration across academia and industry, and delivering innovations that can improve patient outcomes worldwide.

As the centre continues to expand its research portfolio and international partnerships, this recognition further reflects the calibre of expertise within Rinn Pharma & Biopharma and its growing contribution to Ireland’s reputation as a global hub for pharmaceutical and biopharmaceutical research.

More news

Rinn Pharma & Biopharma Leadership Team Joins Research Ireland Innovation Mission to Boston

Rinn Pharma & Biopharma Leadership Team Joins Research Ireland Innovation Mission to Boston

Rinn Pharma & Biopharma’s leadership team recently participated in a Research Ireland Innovation Mission to Boston, joining leading researchers, innovators and policymakers to explore one of the world’s most successful biotech ecosystems. Throughout the week, the delegation engaged with globally recognised organisations including MIT, the Broad Institute, Boston Scientific and LabCentral, gaining valuable insights into research translation, entrepreneurship and innovation-led growth. Highlighting the importance of international collaborations while strengthening links between Ireland’s research community and leading global innovation hubs.

read more